Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ultragenyx Pharmaceutical Inc.

< Previous 1 2 3 4 Next >
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers MREO RARE
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate at Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers MREO RARE
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.